Mayo Clinic study finds IL-6 receptor blockers effective in preventing relapses of rare neurological disease MOGAD

An international study led by Mayo Clinic researchers and published in JAMA Neurology in August 2026 indicates that interleukin-6 (IL-6) receptor blockers, specifically tocilizumab and satralizumab, are effective in preventing relapses of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Evaluating 116 patients across North and South America, the study found that patients experienced significantly fewer relapses and a generally favorable safety profile, though infection risks remain.

IL-6 receptor blockers efficacy

• ▪Researchers believe the immune signaling protein interleukin-6 plays an important role in the inflammation that damages myelin in people diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease.
• ▪A Mayo Clinic-led study published in JAMA Neurology in August 2026 identified interleukin-6 receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease.

MOGAD autoimmune disease mechanism

• ▪Myelin oligodendrocyte glycoprotein antibody-associated disease is a rare autoimmune neurological disorder that can cause vision loss, paralysis, and other serious neurological complications.
• ▪Myelin oligodendrocyte glycoprotein antibody-associated disease occurs when the immune system mistakenly attacks myelin, the protective coating surrounding nerve fibers in the brain, spinal cord, and optic nerves.
• ▪There are currently no treatments approved specifically to prevent relapses in patients diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease.

Tocilizumab satralizumab treatment outcomes

• ▪The interleukin-6 receptor blockers tocilizumab and satralizumab demonstrated a generally favorable safety profile in patients, though infections remain an important consideration for clinicians.
• ▪Patients with myelin oligodendrocyte glycoprotein antibody-associated disease had substantially fewer relapses after starting treatment with the interleukin-6 receptor blockers tocilizumab or satralizumab.
• ▪The Mayo Clinic-led study on myelin oligodendrocyte glycoprotein antibody-associated disease evaluated two interleukin-6 receptor blocker medications, tocilizumab and satralizumab.

Multinational collaborative study design

• ▪The observational study led by Mayo Clinic researchers evaluated 116 patients treated with interleukin-6 receptor blockers across multiple medical centers in North and South America.
• ▪Most participants in the 116-patient observational study on myelin oligodendrocyte glycoprotein antibody-associated disease received the drug tocilizumab, while a smaller number received satralizumab.

Ongoing MOGAD clinical trials

• ▪The observational study published in JAMA Neurology provides real-world evidence to help guide treatment decisions for myelin oligodendrocyte glycoprotein antibody-associated disease while randomized clinical trials are pending.
• ▪Multiple clinical trials evaluating treatments for myelin oligodendrocyte glycoprotein antibody-associated disease are underway to provide randomized clinical trial results.

1 source